A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

To investigate tolerability, efficacy, and pharmacokinetics/pharmacodynamics of Debio 1347, a selective FGFR inhibitor. This was a first-in-human, multicenter, open-label study in patients with advanced solid tumors harboring gene alterations. Eligible patients received oral Debio 1347 at escalating...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 25; no. 9; p. 2699
Main Authors:	Voss, Martin H, Hierro, Cinta, Heist, Rebecca S, Cleary, James M, Meric-Bernstam, Funda, Tabernero, Josep, Janku, Filip, Gandhi, Leena, Iafrate, A John, Borger, Darrell R, Ishii, Nobuya, Hu, Youyou, Kirpicheva, Yulia, Nicolas-Metral, Valerie, Pokorska-Bocci, Anna, Vaslin Chessex, Anne, Zanna, Claudio, Flaherty, Keith T, Baselga, Jose
Format:	Journal Article
Language:	English
Published:	United States 01.05.2019
Subjects:	Adult Aged Benzimidazoles - pharmacokinetics Benzimidazoles - therapeutic use Drug Administration Schedule Female Follow-Up Studies Gene Fusion Humans Male Maximum Tolerated Dose Middle Aged Mutation Neoplasms - drug therapy Neoplasms - genetics Neoplasms - pathology Prognosis Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - therapeutic use Pyrazoles - pharmacokinetics Pyrazoles - therapeutic use Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors Receptor, Fibroblast Growth Factor, Type 1 - genetics Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors Receptor, Fibroblast Growth Factor, Type 2 - genetics Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors Receptor, Fibroblast Growth Factor, Type 3 - genetics Signal Transduction Tissue Distribution
ISSN:	1557-3265, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!